This company is involved in the development of treatments for rare diseases, with FDA-approved drugs and orphan drug designations targeting conditions like nevoid basal cell carcinoma syndrome and inherited ichthyosis.
2
Orphan Designations
0 approved, 2 designated
10
FDA Approvals
Latest: NEXTSTELLIS (2021)
0
Active Trials
4
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Mayne Pharma is a company with 2 orphan drug designations across 4 rare diseases, including 10 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| basal cell nevus syndrome 1 | Itraconazole | Des.TrialAppr. |
| basal cell nevus syndrome 2 | Itraconazole | Des.TrialAppr. |
| inherited ichthyosis | trifarotene | Des.TrialAppr. |
| nevoid basal cell carcinoma syndrome | Itraconazole | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio